Paper42465751
Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.
Kudriavskii VV and 3 others. Front Immunol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets. Papers, record 42465751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42465751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Antigens, Neoplasm | Major topic |
| Immunotherapy | Major topic |
| Humans | |
| Animals | |
| Epitopes | |
| Alternative Splicing |
Source PubMed
References184
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31278396 | Alternative tumour-specific antigens. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/31278396 | PubMed |
| 2 | 35904353 | Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. | Cancer Res | 2022 | https://conductscience.org/library/papers/35904353 | PubMed |
| 3 | 36735774 | Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. | Sci Immunol | 2023 | https://conductscience.org/library/papers/36735774 | PubMed |
| 4 | 33328638 | Anti-tumour immunity induces aberrant peptide presentation in melanoma. | Nature | 2021 | https://conductscience.org/library/papers/33328638 | PubMed |
| 5 | 40866359 | Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells. | Nat Commun | 2025 | https://conductscience.org/library/papers/40866359 | PubMed |
| 6 | 39578174 | Generation of tumor neoantigens by RNA splicing perturbation. | Trends Cancer | 2025 | https://conductscience.org/library/papers/39578174 | PubMed |
| 7 | 38759626 | Arginine deprivation enriches lung cancer proteomes with cysteine by inducing arginine-to-cysteine substitutants. | Mol Cell | 2024 | https://conductscience.org/library/papers/38759626 | PubMed |
| 8 | 35264796 | Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. | Nature | 2022 | https://conductscience.org/library/papers/35264796 | PubMed |
| 9 | 37254712 | Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37254712 | PubMed |
| 10 | 40756430 | Properties of CD8 T-cell-recognized neoantigens in different tumor types. | Immunooncol Technol | 2025 | https://conductscience.org/library/papers/40756430 | PubMed |
| 11 | 28198830 | 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. | Nat Immunol | 2017 | https://conductscience.org/library/papers/28198830 | PubMed |
| 12 | 38538867 | A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. | Nat Med | 2024 | https://conductscience.org/library/papers/38538867 | PubMed |
| 13 | 38600345 | The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing. | EMBO Rep | 2024 | https://conductscience.org/library/papers/38600345 | PubMed |
| 14 | 39588782 | Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/39588782 | PubMed |
| 15 | 33363023 | Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/33363023 | PubMed |
| 16 | 32866021 | Proteome-Wide Analysis of ADAR-Mediated Messenger RNA Editing during Fruit Fly Ontogeny. | J Proteome Res | 2020 | https://conductscience.org/library/papers/32866021 | PubMed |
| 17 | 18806759 | E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. | Cell Death Differ | 2008 | https://conductscience.org/library/papers/18806759 | PubMed |
| 18 | 34297039 | ADAR and hnRNPC deficiency synergize in activating endogenous dsRNA-induced type I IFN responses. | J Exp Med | 2021 | https://conductscience.org/library/papers/34297039 | PubMed |
| 19 | 42086309 | Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42086309 | PubMed |
| 20 | 38506710 | Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38506710 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42465751
GET https://conductscience.org/api/papers/v1/42465751/references?page=2